1.	Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: C14012, 2011-003545-18, NCT01482962
2.	Phase 3 Multi-center Randomized Study to Compare Efficacy and Safety of Romidepsin CHOP (Ro-CHOP) Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma Phase: Phase III Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: Ro-CHOP Study, NCT01796002
3.	A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma Phase: Phase II, Phase I Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: 06/34, NCT00431990
4.	Phase I/II Study of Romidepsin and Erlotinib Hydrochloride in Patients With Stage IIIB or IV Non-Small Cell Lung Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: SCCC-12508, SCCC-12508, NCT01302808
5.	A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 70 Sponsor: Other Protocol IDs: Ro-CHOP, NCT01280526
6.	A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL) Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ROMI-TCL-001, NCT01456039
7.	An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study) Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: 1112009392, 115541, NCT01742793
8.	Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 12-170, NCT01755975
9.	A Single Agent Phase II Study of Depsipeptide (FK228) in the Treatment of Cutaneous T-Cell Lymphoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GPI-04-0001, UCLA-0509044-01A, NCT00106431
10.	A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide. Phase: Phase II Type: Treatment Status: Approved-not yet active Age: Not specified Sponsor: Other Protocol IDs: CCR2742, NCT00299351
11.	Phase IIa Study on the Role of Gemcitabine Plus Romidepsin (GEMRO Regimen) in the Treatment of Relapsed/Refractory Peripheral T-cell Lymphoma Patients. Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FIL_GEMRO, NCT01822886
12.	Bortezomib and Romidepsin in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Indolent B-cell Lymphoma, Peripheral T-cell Lymphoma or Cutaneous T-Cell Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: MCC-12215, P30CA016059, R21CA137823, CDR0000652509, MCV-MCC-X05240, MCC-X05240, NCT00963274
13.	Phase I Study of Romidepsin Plus ICE for Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 2012-0183, NCT01590732
14.	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-01040, J11105, CDR0000737061, U01CA070095, U01CA132123, U01CA062505, NCT01638533
15.	Dose-Escalation Trial of Carfilzomib With and Without Romidepsin in Cutaneous T-Cell Lymphoma Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NU 12H06, STU00071042, NCI-2012-01952, NCT01738594
16.	A Trial of Oral 5-azacitidine in Combination With Romidepsin in Advanced Solid Tumors, With an Expansion Cohort in Non-small Cell Lung Cancer Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: J11102, NA_00052054, NCT01537744